Migliorati Cesar A, Hsu Chiu-Jen, Chopra Sonia, Kaltman Steven S
Nova Southeastern University, College of Dental Medicine, Fort Lauderdale, Fla 33328, USA.
J Calif Dent Assoc. 2008 Oct;36(10):769-74.
Bisphosphonate osteonecrosis, BON, was recently described in the literature. Lack of scientific evidence explaining the pathophysiologic mechanisms involved in the development of this oral complication has generated uncertainties about proper management of patients treated with a bisphosphonate. This manuscript discusses the dental management of two breast cancer patients treated with intravenous bisphosphonates as part of their cancer management and who developed oral disease. Clinical management decisions will be presented as well as the treatment outcomes.
双膦酸盐性骨坏死（BON）最近在文献中有所描述。由于缺乏科学证据来解释这种口腔并发症发生发展过程中涉及的病理生理机制，导致在双膦酸盐治疗患者的恰当管理方面存在不确定性。本文讨论了两名乳腺癌患者的牙科管理情况，这两名患者在癌症治疗过程中接受了静脉注射双膦酸盐治疗，并出现了口腔疾病。文中将介绍临床管理决策以及治疗结果。
